stannic protoporfin
Biologicalexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2020 (NCT04364763)
Timeline
Indications
Studied for
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
- Mol. weight
- 750.27 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314609 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06021457 | Phase 3 | Oct 17, 2023 | Renibus Therapeutics, Inc. |
| NCT04364763 | Phase 2 | Jun 1, 2020 | Renibus Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Renibus Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1